Clinical Trial Update: The Immunogenicity of Intradermal Influenza Vaccination in Hemodialysis Patients [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating the immunogenicity of intradermal influenza vaccination in patients with end-stage renal disease on hemodialysis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• Influenza vaccine (intradermal) (intradermal influenza vaccine)

Snippet

Sponsor: Shiraz University of Medical Sciences | Conditions: Hemodialysis Patients | Phase 2, Phase 3 | Status: COMPLETED